After the sale of its Chemical Development Division to Olon S.p.A., Ricerca Biosciences is being renamed Concord Biosciences. Concord Biosciences is a strong and experienced CRO that will continue its decades-long emphasis on active pharmaceutical and non-pharmaceutical ingredient safety and metabolism, bioanalytical, and agrochemical research.
Main Market Partners a middle-market growth investment fund and owner of Concord Biosciences, has indicated it intends on continuing to grow the company and invest in its people. Concord Biosciences, remains devoted to performing exceptional contract research and delivering extraordinary value to its clients.
"We are very pleased to focus our complete energies on our Safety and Metabolism (Drug, AgChem, and Chemical), Bioanalytical, and Agrochemical clients after the sale of our Chemical Development Division," According to Clifford W. Croley of Main Market Partners and the CEO of Concord Biosciences.
Concord Biosciences, collaborates with pharmaceutical and biopharmaceutical developers by providing an integrated suite of pre-clinical services to accelerate drug development. The company provides:
- Non-clinical toxicology
- In-vitro metabolism
- Dose formulation
- Method development
- Bioanalytical support services
Concord Biosciences, will continue to collaborate with its former Chemical Development Division's new owners to bring drug and chemical candidates through all phases of development. Over the past 31 years, Concord Biosciences has supported its clients through the entire R&D process to bring drugs and compounds through development and ultimately to the market.